Trial Profile
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Apr 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Lung-Map Sub-Study
- 21 Apr 2023 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.
- 10 Jan 2023 Results comparing quality-of-life in patients from this study was published in the Journal of the National Cancer Institute.
- 06 May 2022 Planned End Date changed from 1 Apr 2022 to 1 Apr 2023.